
Zynex, Inc. Investor Alert: Rosen Law Firm Encourages Shareholders to Seek Guidance Before Important Deadline in Securities Class Action.
ROSEN NATIONAL INVESTOR COUNSEL Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Lawsuit
NEW YORK, April 25, 2022 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Zynex, Inc. (NASDAQ: ZYXI) securities between April 29, 2021 and March 2, 2022, of the important April 25, 2022 lead plaintiff deadline in the securities class action lawsuit filed by the firm.
The lawsuit alleges that Zynex, Inc. and certain of its officers and directors made false and misleading statements and failed to disclose material information during the class period, causing Zynex, Inc. securities to be traded at artificially inflated prices.
According to the lawsuit, Zynex, Inc. made false and/or misleading statements and failed to disclose that: (1) the Company's non-invasive blood glucose monitoring technology was not as effective as the Company had claimed; and (2) the Company was experiencing significant delays and difficulties in the development and launch of its new products, including the B-100 and B-200 devices.
On March 2, 2022, the Company announced that it would delay the launch of its new products and that its non-invasive blood glucose monitoring technology was not as effective as previously claimed. On this news, Zynex, Inc. shares declined significantly, causing investors to suffer substantial losses.
A class action lawsuit has already been filed. If you purchased Zynex, Inc. securities between April 29, 2021 and March 2, 2022, you may be able to participate in the action. To join this action, or to discuss your rights and options, contact a Rosen Law Firm representative at www.rosenlegal.com or toll-free at 866-767-3653.
Rosen Law Firm represents investors worldwide, focusing exclusively on securities based litigation and arbitration. The firm has secured hundreds of millions of dollars for its clients and has been recognized by various organizations and publications for its expertise in this area.
Follow us for updates on this and other cases: www.twitter.com/rosenlawus. |end_of_text|